Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit

Abstract

Response to: Duprez D, Toleuova A. Prehypertension and the cardiometabolic syndrome: pathological and clinical consequences. Expert Rev Cardiovasc Ther 2013;11(12):1725-33

Financial & competing interests disclosure

N Katsiki has given talks and attended conferences sponsored by Novartis, Pfizer, MSD and AstraZeneca. A Karagiannis has given talks and attended conferences sponsored by Menarini, AstraZeneca, Novartis and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.